- Home
- VHC vs CUE Comparison
VHC vs CUE Comparison
Compare VHC & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VHC
- CUE
- Stock Information
- Founded
- VHC 2005
- CUE 2014
- Country
- VHC United States
- CUE United States
- Employees
- VHC N/A
- CUE N/A
- Industry
- VHC Multi-Sector Companies
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- VHC Miscellaneous
- CUE Health Care
- Exchange
- VHC Nasdaq
- CUE Nasdaq
- Market Cap
- VHC 54.3M
- CUE 59.5M
- IPO Year
- VHC 1999
- CUE 2018
- Fundamental
- Price
- VHC $18.88
- CUE $0.78
- Analyst Decision
- VHC
- CUE Strong Buy
- Analyst Count
- VHC 0
- CUE 2
- Target Price
- VHC N/A
- CUE $3.00
- AVG Volume (30 Days)
- VHC 9.6K
- CUE 108.9K
- Earning Date
- VHC 08-12-2025
- CUE 08-12-2025
- Dividend Yield
- VHC N/A
- CUE N/A
- EPS Growth
- VHC N/A
- CUE N/A
- EPS
- VHC N/A
- CUE N/A
- Revenue
- VHC $50,000.00
- CUE $8,286,000.00
- Revenue This Year
- VHC N/A
- CUE N/A
- Revenue Next Year
- VHC N/A
- CUE $10.19
- P/E Ratio
- VHC N/A
- CUE N/A
- Revenue Growth
- VHC 733.33
- CUE N/A
- 52 Week Low
- VHC $3.68
- CUE $0.45
- 52 Week High
- VHC $21.53
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- VHC 65.48
- CUE 44.82
- Support Level
- VHC $14.30
- CUE $0.77
- Resistance Level
- VHC $20.11
- CUE $0.89
- Average True Range (ATR)
- VHC 1.32
- CUE 0.04
- MACD
- VHC 0.66
- CUE -0.01
- Stochastic Oscillator
- VHC 83.84
- CUE 5.98
About VHC VirnetX Holding Corp
VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. The company's software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.